Gentherm (NASDAQ:THRM) Stock

Gentherm

Gentherm Inc is an automotive parts manufacturer. The business activities of the group function through the Automotive and Medical segments. The vast majority of the firm's revenue comes from the Automotive segment, which includes automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronics and software systems. The medical segment is comprised of the results from the patient temperature management business in the medical industry. Its geographical segments are the United States, China, South Korea, Germany, Japan, the Czech Republic, and other countries.

Movers_Stocks

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

BMBL

ETSY

INNV

SLSR

SUPN

THRM

Gentherm Posts Downbeat Results, Joins Celanese, Bumble And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

movers image

ADTX

APTO

CYCU

DSGN

MGOL

MOVE

NEXA

NIVF

OSRH

RSLS

SINT

TRUG

Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

Earnings

Small Cap

Analyst Ratings

Tech

CTSH

Cognizant Technology Solutions (NASDAQ: CTSH) benefits from an expanding portfolio with the recent launch of Neuro Edge, a new platform in its Neuro suite.

Cognizant Expands Neuro Suite With Edge AI Platform

Gentherm Inc

Baird analyst Luke Junk maintains Gentherm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) with a Neutral and lowers the price target from $44 to $39.

Price Target

Baird Maintains Neutral on Gentherm, Lowers Price Target to $39

U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Wednesday.
Shares of Gentherm Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/quote/THRM/news">weak quarterly results.</a>
Gentherm shares dipped 17% to $30.00 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) fell 22% to $31.00 in pre-market trading after the company announced that the Phase 2b study of SPN-820 in adults with treatment-resistant depression did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale.</li>
<li>InnovAge Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) fell 21.1% to $2.70 in today's pre-market trading. InnovAge recently reported worse-than-expected second-quarter financial results.</li>
<li>Bumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) declined 17.3% to $6.70 in pre-market trading after the company issued first-quarter revenue guidance below estimates and announced a quarter-over-quarter decline in paying app users.</li>
<li>GCL Global Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCL#NASDAQ">GCL</a>) fell 14.7% to $6.40 in pre-market trading after jumping 153% on Tuesday.</li>
<li>Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) shares dipped 13.5% to $60.50 in pre-market trading after the company issued first-quarter EPS guidance below estimates.</li>
<li>Koninklijke Philips N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) declined 11.9% to $24.94 in pre-market trading following weak quarterly results.</li>
<li>Solaris Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLSR#NYSE">SLSR</a>) fell 7.7% to $3.60 in pre-market trading.</li>
<li>Etsy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) declined 6.8% to $53.35 in pre-market trading after reporting a 6.8% YoY decline in fourth-quarter GMV and guiding for a similar YoY GMV decline in the first quarter.</li>
<li>Toll Brothers, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) fell 5.4% to $115.50 in pre-market trading after the company reported worse-than-expected first-quarter financial results..</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43776863/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter-3">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

Gentherm Posts Downbeat Results, Joins Celanese, Bumble And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

WIIM

Gentherm shares are trading lower after the company missed Q4 EPS and revenue estimates.

Shares of Global Blue Group Holding AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GB#NYSE">GB</a>) rose sharply during Wednesday's pre-market trading session after the company announced it will be acquired by Shift4 for <a href="https://www.benzinga.com/quote/gb/analyst-ratings">$7.50 per share</a>.
Global Blue Group shares jumped 18.3% to $7.37 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Cycurion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCU#NASDAQ">CYCU</a>) rose 132.5% to $7.79 in pre-market trading after dipping 72% on Tuesday.</li>
<li>OSR Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) shares jumped 96.4% to $6.11 in pre-market trading after gaining 3% on Tuesday.</li>
<li>Lytus Technologies Holdings PTV. Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYT#NASDAQ">LYT</a>) gained 52.7% to $0.34 in pre-market trading after dipping 14% on Tuesday.</li>
<li>ReShape Lifesciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) gained 43.3% to $1.55 in pre-market trading. ReShape Lifesciences shares dipped around 54% on Tuesday after the company announced a $6 million public offering of 2,575,107 units at $2.33 per unit.</li>
<li>Sintx Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares climbed 38.3% to $3.90 in pre-market trading. Sintx Technologies announced the issuance of U.S. patent no. 12,239,761 by the United States Patent and Trademark Office.</li>
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) gained 35.2% to $2.96 in pre-market trading after gaining around 12% on Tuesday.</li>
<li>TruGolf Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>) gained 33.1% to $0.5444 in pre-market trading after the company guided 2024 sales of $22.5 million and 2H adjusted EBITDA above $2.2 million.</li>
<li>Aditxt, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) gained 22.3% to $0.1345 in pre-market after surging 57% on Tuesday.</li>
<li>Mercurity Fintech Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NASDAQ">MFH</a>) rose 14.5% to $8.00. MFH&#8217;s majority-owned subsidiary Aifinity Base Limited plans to manufacture advanced liquid cooling solutions for Nvidia&#xAE; chip-powered AI data centers and high-performance computing.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Movano Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOVE#NASDAQ">MOVE</a>) shares fell 36.4% to $3.25 in pre-market trading.</li>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) shares fell 25.5% to $0.1439 in pre-market trading after gaining around 8% on Tuesday.</li>
<li>Design Therapeutics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) dipped 24.5% to $3.120 in pre-market trading.</li>
<li>Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) fell 22% to $31.00 in pre-market trading after the company announced that the Phase 2b study of SPN-820 in adults with treatment-resistant depression did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale.</li>
<li>InnovAge Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) fell 21.1% to $2.70 in today's pre-market trading. InnovAge recently reported worse-than-expected second-quarter financial results.</li>
<li>MGO Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) shares tumbled 20.9% to $0.3680 in pre-market trading after dipping 35% on Tuesday. MGO Global&#8217;s stockholders approved business combination with Heidmar.</li>
<li>Bumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) declined 17.3% to $6.70 in pre-market trading after the company issued first-quarter revenue guidance below estimates and announced a quarter-over-quarter decline in paying app users.</li>
<li>Gentherm Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) fell 17% to $30.00 in pre-market trading following weak quarterly results.</li>
<li>Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) shares dipped 13.5% to $60.50 in pre-market trading after the company issued first-quarter EPS guidance below estimates.</li>
<li>Nexa Resources S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEXA#NYSE">NEXA</a>) fell 10.6% to $4.60 in pre-market trading following a 7% decline on Tuesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43776863/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter-3">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

Guidance

Gentherm Sees FY25 Product Revenues Of $1.4b - $1.5B Vs. $1.54B Est.

Gentherm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) reported quarterly adjusted earnings of $0.29 per share which missed the analyst consensus estimate of $0.68 by 57.35 percent. This is a 67.78 percent decrease over earnings of $0.90 per share from the same period last year. The company reported quarterly sales of $352.91 million which missed the analyst consensus estimate of $360.29 million by 2.05 percent. This is a 3.82 percent decrease over sales of $366.93 million the same period last year.

Earnings Misses

Gentherm Q4 Adj $0.29 Misses $0.68 Estimate, Sales $352.91M Miss $360.29M Estimate

ACVA

AMPL

ANSS

APPN

BLCO

BMRN

BORR

CAKE

CCAP

CCSI

CHDN

CLVT

CMTG

CVNA

CWAN

ENLT

ENVX

ESRT

EXAS

FOLD

First Trust Advantage Preferred Income Fund

FVRR

GLBE

GRAB

GRMN

HSBC

ICLR

IIPR

IMAX

INSG

IONS

KALU

KPTI

KRYS

KVYO

LAND

LILA

LILAK

LOPE

LUNG

MANU

MATV

MGRC

MTRN

NDSN

NRDS

NYMT

OBDC

PAAS

PERI

PNST

PRAA

Earnings Scheduled For February 19, 2025

JP Morgan analyst Ryan Brinkman maintains Gentherm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) with a Neutral and lowers the price target from $56 to $51.

JP Morgan Maintains Neutral on Gentherm, Lowers Price Target to $51

Management

Gentherm Appoints Jonathan Douyard As Executive Vice President, CFO And Treasurer

Phil Eyler to Remain as an Advisor to Gentherm through June 30, 2025.

Gentherm Plans CEO Succession In 2025; Bill Presley To Become President And CEO, And Board Director, As Of January 1, 2025

Craig-Hallum analyst Ryan Sigdahl maintains Gentherm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) with a Buy and lowers the price target from $85 to $65.

Craig-Hallum Maintains Buy on Gentherm, Lowers Price Target to $65

Baird analyst Luke Junk maintains Gentherm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) with a Neutral and lowers the price target from $54 to $50.

Baird Maintains Neutral on Gentherm, Lowers Price Target to $50

Guidance The Company's full-year 2024 guidance as of October 30, 2024 is shown below:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>As of July 31, 2024</td>
<td>As of October 30, 2024(1)</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Product Revenues</td>
<td>Low end of $1.5B – $1.6B</td>
<td>$1.45B – $1.47B</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Adjusted EBITDA Margin Rate</td>
<td>Above mid-point of 12.5% – 13.5%</td>
<td>Near mid-point of 12.5% – 13.5%</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Full-year Adjusted Effective Tax Rate</td>
<td>26% – 29%</td>
<td>No change</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Capital Expenditures</td>
<td>$65M – $75M</td>
<td>No change</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="4">(1)&nbsp;Based on the current forecast of customer orders, our expectations of near-term conditions, and light vehicle production in our relevant markets decreasing at low to mid-single digit rate for full year 2024 versus 2023, and a EUR to USD exchange rate of $1.08/Euro.</td>
</tr>
</tbody>
</table>
</figure>

Gentherm 2024 Outlook: Sees Revenue Of $1.45B–$1.47B (Prior $1.5B-$1.6B) Vs. $1.50B Est

Earnings Beats

Gentherm Q3 2024 Adj. EPS $0.75 Beats $0.66 Estimate, Sales $371.512M Miss $373.676M Estimate

Gentherm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) will release its quarterly earnings report on Wednesday, 2024-10-30. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Gentherm to report an earnings per share (EPS) of $0.66.
Anticipation surrounds Gentherm's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Past Earnings Performance</h3>
The company's EPS beat by $0.05 in the last quarter, leading to a 1.96% drop in the share price on the following day.
Here's a look at Gentherm's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.61</td>
<td>0.43</td>
<td>0.52</td>
<td>0.68</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.66</td>
<td>0.62</td>
<td>0.90</td>
<td>0.64</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>3.0%</td>
<td>-1.0%</td>
<td>-8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730228486_0.png" alt="eps graph" />
<h3>Performance of Gentherm Shares</h3>
Shares of Gentherm were trading at $41.7 as of October 28. Over the last 52-week period, shares are up 5.48%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Take on Gentherm</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Gentherm.
Analysts have given Gentherm a total of 1 ratings, with the consensus rating being Neutral. The average one-year price target is $56.0, indicating a potential 34.29% upside.
<h3>Peer Ratings Comparison</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of XPEL, Dana and Fox Factory Hldg, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for XPEL, with an average 1-year price target of $58.0, suggesting a potential 39.09% upside.</li>
<li>The prevailing sentiment among analysts is an Neutral trajectory for Dana, with an average 1-year price target of $13.33, implying a potential 68.03% downside.</li>
<li>As per analysts' assessments, Fox Factory Hldg is favoring an Neutral trajectory, with an average 1-year price target of $46.75, suggesting a potential 12.11% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
The peer analysis summary offers a detailed examination of key metrics for XPEL, Dana and Fox Factory Hldg, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gentherm</td>
<td>Neutral</td>
<td>0.90%</td>
<td>$96.70M</td>
<td>2.93%</td>
</tr>
<tr>
<td>XPEL</td>
<td>Buy</td>
<td>7.51%</td>
<td>$47.87M</td>
<td>7.74%</td>
</tr>
<tr>
<td>Dana</td>
<td>Neutral</td>
<td>-0.36%</td>
<td>$255M</td>
<td>1.06%</td>
</tr>
<tr>
<td>Fox Factory Hldg</td>
<td>Neutral</td>
<td>-13.03%</td>
<td>$110.96M</td>
<td>0.45%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Gentherm is positioned in the middle among its peers for revenue growth, with one peer showing the highest growth rate. In terms of gross profit, Gentherm ranks second highest. However, Gentherm has the highest return on equity compared to its peers.
<h3>About Gentherm</h3>
Gentherm Inc is an automotive parts manufacturer. The business activities of the group function through the Automotive and Medical segments. The vast majority of the firm's revenue comes from the Automotive segment, which includes automotive climate comfort systems, automotive cable systems, battery performance solutions and automotive electronics and software systems. The medical segment is comprised of the results from the patient temperature management business in the medical industry. Its geographical segments are the United States, China, South Korea, Germany, Japan, the Czech Republic, and other countries.
<h3>Breaking Down Gentherm's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Gentherm showcased positive performance, achieving a revenue growth rate of 0.9% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Gentherm's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 5.02%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Gentherm's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.93%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Gentherm's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.51%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Gentherm's debt-to-equity ratio is below the industry average at 0.39, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/THRM/earnings">To track all earnings releases for Gentherm visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Gentherm

JP Morgan analyst Ryan Brinkman upgrades Gentherm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) from Underweight to Neutral and maintains the price target from $56 to $56.

Upgrades

JP Morgan Upgrades Gentherm to Neutral, Maintains Price Target to $56

Effective September 1, 2024; Anversa To Join Logitech International As CFO

LOGI

Gentherm Announces Resignation Of CFO Matteo Anversa

Guidance
The Company&#39;s full-year 2024&nbsp;guidance&nbsp;as of July 31, 2024 is shown below:
<table align="center">
<tbody>
<tr>
<td>Initial 2024&nbsp;Guidance</td>
<td>Latest Estimate(1)</td>
</tr>
<tr>
<td>Product Revenues</td>
<td>$1.5B&nbsp;&ndash;&nbsp;$1.6B</td>
<td>Low end of range</td>
</tr>
<tr>
<td>Adjusted EBITDA Margin Rate</td>
<td>12.5%&nbsp;&ndash;&nbsp;13.5%</td>
<td>Above mid-point of range</td>
</tr>
<tr>
<td>Full-year Adjusted Effective Tax Rate</td>
<td>26%&nbsp;&ndash;&nbsp;29%</td>
<td>No change</td>
</tr>
<tr>
<td>Capital Expenditures</td>
<td>$65M&nbsp;&ndash;&nbsp;$75M</td>
<td>No change</td>
</tr>
<tr>
		</tr>
<tr>
<td colspan="4">(1) Based on the current forecast of customer orders, and light vehicle production in the Company&#39;s key markets declining at a low single digit rate in 2024 versus 2023, and a EUR to USD exchange rate of&nbsp;$1.08/Euro for the remainder of the year.</td>
</tr>
</tbody>
</table>

Gentherm 2024 Outlook: Sees Revenue Of $1.5b-$1.6b Vs. $1.527b Est.; And Adjusted EBITDA Margin Of 12.5%-13.5%

Gentherm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) reported quarterly earnings of $0.66 per share which beat the analyst consensus estimate of $0.61 by 8.2 percent. This is a 13.79 percent increase over earnings of $0.58 per share from the same period last year. The company reported quarterly sales of $375.683 million which beat the analyst consensus estimate of $374.152 million by 0.41 percent. This is a 0.90 percent increase over sales of $372.323 million the same period last year.

Gentherm Q2 2024 Adj. EPS $0.66 Beats $0.61 Estimate, Sales $375.683M Beat $374.152M Estimate

JP Morgan analyst Ryan Brinkman maintains Gentherm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) with a Underweight and lowers the price target from $60 to $56.

JP Morgan Maintains Underweight on Gentherm, Lowers Price Target to $56

Press Releases

Gentherm Reports 2024 Second Quarter Results

Gentherm Announces Departure of its Chief Financial Officer

Gentherm Announces Date for 2024 Third Quarter Results News Release and Conference Call

Gentherm to Participate in the 2024 Baird Global Industrial Conference

Gentherm Reports 2024 Third Quarter Results

Gentherm Announces CEO Succession in 2025

Gentherm Announces Updated Fireside Chat Time for 2024 Baird Global Industrial Conference

Gentherm Names Jonathan Douyard as Executive Vice President, Chief Financial Officer and Treasurer

Gentherm Announces Date for 2024 Fourth Quarter and Year-End Results News Release and Conference Call

Gentherm Reports 2024 Fourth Quarter and Full Year Results

SHYF

Adient

Autoliv

American Axle & Manufacturing Holdings, Inc. Common Stock

American Axle & Mfg Hldgs

BorgWarner

Cooper-Standard Holdings Inc. Common Stock

Cooper-Standard Holdings

Dana

Dorman Prods

ECARX Holdings Inc. - Class A Ordinary shares

ECARX Holdings

Fox Factory Hldg

Gentex

Garrett Motion

Holley

Hesai Group - American Depositary Share, each ADS represents one Class B ordinary share

Comments

Gentherm

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga